Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients-Reference-Cited by-同舟云学术

Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients

Published:2023-03 Issue: Volume:126 Page:107021
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Mohammadi Fatemeh,Rostami Golale,Hamid Mohammad,Shafiei Mohammad,Azizi Masoumeh,Bahmani Hasan

Funder

Pasteur Institute of Iran

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference36 articles.

1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia;Hochhaus;Leukemia,2020

2. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia;Ni;Med. Oncol.,2011

3. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib;Vivona;Blood Cells Mol. Dis.,2012

4. Association of SLC22A1, SLCO1B3 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in patients with chronic myeloid leukemia;Mohammadi;Lab. Med.,2021

5. Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death;Lauseker;Cancer,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel fluorescent probe based imprinted polymer-coated magnetite for the detection of imatinib leukemia anti-cancer drug traces in human plasma samples;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2024-07